×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Merck's BCG monopoly could end
Fierce Pharma
ImmunityBio last week won the FDA's approval for its immunotherapy Anktiva to be used alongside the Bacillus Calmette-Guérin (BCG) vaccine...
2 days ago
Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda
Reuters
Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug...
1 week ago
Our Q1 2024 earnings report
Merck.com
Merck's (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of...
1 week ago
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations.
5 days ago
Merck & Co employee number 2008-2023
Statista
Merck & Co. number of employees 2008-2023 ... Merck & Co. is a global health care and pharmaceutical company that is headquartered in Kenilworth,...
2 months ago
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC
Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug...
1 week ago
Merck & Co., Inc. (NYSE:MRK) Stock Price Down 0.8%
Defense World
Read Merck & Co., Inc. (NYSE:MRK) Stock Price Down 0.8% at Defense World.
19 hours ago
Healthcare - Company
Merck KGaA
With a holistic approach, we design and develop medicines and intelligent devices that provide ongoing care for patients beyond their treatment. This includes...
2 months ago
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine ...
GlobeNewswire
PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle...
15 minutes ago
FDA Approves Merck's WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial ...
Merck.com
March 26, 2024 6:21 pm ET. WINREVAIR is a breakthrough biologic for this rare, progressive disease. WINREVAIR on top of background therapy significantly...
1 month ago